Stem cell innovators
Professor Peter Andrews has devoted his research career to studying the biology of human embryonic stem (ES) cells and their malignant counterparts, embryonal carcinoma (EC) cells. Prof. Andrews was the first scientist in the UK to work with human ES cells, following the first derivation in 1998. Prof. Andrews’ laboratory studies the causes and consequences of the non-random genetic abnormalities observed in human ES cells after prolonged culture, as well as the progression of stem cell-based cancers. Further work is focused on using induced pluripotent stem (iPS) cell techniques to establish models to study pediatric cancers. Prof. Andrews was a co-founder and director of Axordia Ltd., one of the UK’s leading hESC companies (now a subsidiary of Pfizer) and has been involved in the derivation of several clinical-grade hESC lines (the Sheffield lines), deposited in the UK Stem Cell Bank. Prof. Andrews coordinated the International Stem Cell Initiative and was the director of the Pluripotent Stem Cell Platform, a hub under the UKRMP. He is also on the editorial board of several stem cell journals.